|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma显示文摘Although liver resection is considered the most effective treatment for hepatocellular carcinoma(HCC), treatment outcomes are unsatisfactory because of the high rate of HCC recurrence. Since we reported hepatitis B e-antigen positivity and high serum hepatitis B virus(HBV) DNA concentrations are strong risk factors for HCC recurrence after curative resection of HBV-related HCC in the early 2000 s, many investigators have demonstrated the effects of viral status on HCC recurrence and post-treatment outcomes. These findings suggest controlling viral status is important to prevent HCC recurrence and improve survival after curative treatment for HBV-related HCC. Antiviral therapy after curative treatment aims to improve prognosis by preventing HCC recurrence and maintaining liver function. Therapy with interferon and nucleos(t)ide analogs may be useful for preventing HCC recurrence and improving overall survival in patients who have undergone curative resection for HBV-related HCC. In addition, reactivation of viral replication can occur after liver resection for HBV-related HCC. Antiviral therapy can be recommended for patients to prevent HBV reactivation. Nevertheless, further studies are required to establish treatment guidelines for patients with HBVrelated HCC. | Shoji Kubo Shigekazu Takemura Shogo Tanaka Hiroji Shinkawa Takayoshi Nishioka Akinori Nozawa Masahiko Kinoshita Genya Hamano Tokuji Ito Yorihisa Urata | 2015 | World Journal of Gastroenterology2015，21，27： | 19 |
| 2 | Systematic review of laparoscopic vs open surgery for colorectal cancer in elderly patients显示文摘AIM: To verify the safety and validity of laparoscopic surgery for the treatment of colorectal cancer in elderly patients.METHODS: A meta-analysis was performed of a systematic search of studies on an electronic database. Studies that compared laparoscopic colectomy(LAC) in elderly colorectal cancer patients with open colectomy(OC) were retrieved, and their short and long-term outcomes compared. Elderly people were defined as 65 years old or more. Inclusion criteria were set at: Resection of colorectal cancer, comparison between laparoscopic and OC and no significant difference in backgrounds between groups.RESULTS: Fifteen studies were identified for analysis. LAC was performed on 1436 patients, and OC performed on 1810 patients. In analyses of short-term outcomes, operation time for LAC was longer than for OC(mean difference = 34.4162, 95%CI: 17.8473-50.9851, P < 0.0001). The following clinical parameters were lower in LAC than in OC: Amount of estimated blood loss(mean difference =-93.3738, 95%CI:-132.3437 to-54.4039, P < 0.0001), overall morbidity(OR = 0.5427, 95%CI: 0.4425-0.6655, P < 0.0001), incisional surgical site infection(OR = 0.6262, 95%CI: 0.4310-0.9097, P = 0.0140), bowel obstruction and ileus(OR = 0.6248, 95%CI: 0.4519-0.8638, P = 0.0044) and cardiovascular complications(OR = 0.4767, 95%CI: 0.2805-0.8101, P = 0.0062). In analyses of long-term outcomes(median follow-up period: 36.4 mo in LAC, 34.3 mo in OC), there was no significant difference in overall survival(mean difference = 0.8321, 95%CI: 0.5331-1.2990, P = 0.4187) and disease specific survival(mean difference = 1.0254, 95%CI: 0.6707-1.5675, P = 0.9209). There was also no significant difference in the number of dissected lymph nodes(mean difference =-0.1360, 95%CI:-4.0553-3.7833, P = 0.9458).CONCLUSION: LAC in elderly colorectal cancer patients had benefits in short-term outcomes compared with OC except operation time. The long-term outcomes and oncological clearance of LAC were similar to that of OC. These results support the assertion that LAC is an effective procedure for elderly patients with colorectal cancer. | Shoichi Fujii Mitsuo Tsukamoto Yoshihisa Fukushima Ryu Shimada Koichi Okamoto Takeshi Tsuchiya Keijiro Nozawa Keiji Matsuda Yojiro Hashiguchi | 2016 | World Journal of Gastrointestinal Oncology2016，8，7： | 10 |
| 3 | Combined choriocarcinoma, neuroendocrine cell carcinoma and tubular adenocarcinoma in the stomach显示文摘We described a patient with adenocarcinoma of the stomach combined with choriocarcinoma and neuroendocrine cell carcinoma. An 85-year-old man visited our hospital because of appetite loss. Gastric fiberscopy revealed a large tumor occupying the cardial region and anterior wall of the gastric body. The patient underwent total gastrectomy with lymphnode dissection and partial resection of the liver. Choriocarcinoma, small cell carcinoma and tubular adenocarcinoma existed in the gastric tumor. The choriocarcinomatous foci contained cells positive for beta-subunit of human chorionic gonadotropin (B-hCG) and human placental lactogen mainly in syncytiotrophoblastic cells. The small cell carcinomatous foci contained cells positive for synaptophysin, neuron-specific enolase (NSE), and chromogranin A. The prognosis for gastric adenocarcinoma with choriocarcinoma and neuroendocrine cell carcinoma is exceedingly poor. This patient died about 2 mo after the first complaint from hepatic failure. This is the first reported case of gastric cancer with these three pathological features. | Yasumitsu Hirano Takuo Hara Hiroshi Nozawa Kaeko Oyama Naohiro Ohta Kenji Omura Go Watanabe Hideki Niwa | 2008 | World Journal of Gastroenterology2008，14，20： | 6 |
| 4 | Nomograms for colorectal cancer:A systematic review显示文摘AIM: To assist in the selection of suitable nomograms for obtaining desired predictions in daily clinicalpractice.METHODS: We conducted electronic searches for journal articles on colorectal cancer(CRC)-associated nomograms using the search terms colon/rectal/colorectal/nomogram. Of 174 articles initially found, we retrieved 28 studies in which a nomogram for CRC was developed.RESULTS: We discuss the currently available CRCassociated nomograms, including those that predict the oncological prognosis, the short-term outcome of treatments, such as surgery or neoadjuvant chemoradiotherapy, and the future development of CRC. Developing nomograms always presents a dilemma. On the one hand, the desire to cover as wide a patient range as possible tends to produce nomograms that are too complex and yet have C-indexes that are not sufficiently high. Conversely, confining the target patients might impair the clinical applicability of constructed nomograms.CONCLUSION: The information provided in this review should be of use in selecting a nomogram suitable for obtaining desired predictions in daily clinical practice. | Kazushige Kawai Eiji Sunami Hironori Yamaguchi Soichiro Ishihara Shinsuke Kazama Hiroaki Nozawa Keisuke Hata Tomomichi Kiyomatsu Junichiro Tanaka Toshiaki Tanaka Takeshi Nishikawa Joji Kitayama Toshiaki Watanabe | 2015 | World Journal of Gastroenterology2015，21，41： | 5 |
| 5 | Inhibition of rheumatoid arthritis by blocking connective tissue growth factor显示文摘The pathogenesis of rheumatoid arthritis(RA) remains to be completely elucidated so far; however, it is known that proinflammatory cytokines play a pivotal role in the induction of RA. Tumor necrosis factor(TNF-α), in particular, is considered to play a central role in bone destruction by mediating the abnormal activation of osteoclasts or the production of proteolytic enzymes through direct or indirect mechanisms. The use of TNF-α blocking agents has a significant impact on RA therapy. Anti-TNF-α blocking agents such as infliximab are very effective for treatment of RA, especially for the prevention of articular destruction. We have previously shown that several proteins exhibited extensive changes in their expression after amelioration of RA with infliximab treatment. Among the proteins, connective tissue growth factor(CTGF) has a significantrole for the development of RA. Herein, we review the function of CTGF in the pathogenesis of RA and discuss the possibility of a novel treatment for RA. We propose that CTGF is a potentially novel effector molecule in the pathogenesis of RA. Blocking the CTGF pathways by biological agents may have great beneficial effect in patients with RA. | Kazuhisa Nozawa Maki Fujishiro Yoshinari Takasaki Iwao Sekigawa | 2014 | World Journal of Orthopedics2014，5，5： | 4 |
| 6 | 阿拉善盟内蒙古绒山羊血液蛋白位点及外貌表型检测显示文摘应用随机整群抽样法,在阿拉善盟抽检了内蒙古绒山羊的2个群体各40只,用淀粉凝胶电泳法测定了33个血液蛋白座位,并对毛色及外貌特征进行了表型检测。结果表明,6个血液蛋白位(Tf、Amy、PA-3、Es-D、Alp和Cat)表现多态性,4个毛色座位有变异,11个外形特征性状中,8个有变异体。平均杂合度分析表明,内蒙古绒山羊的变异程度小于辽宁绒山羊等品种。检测结果认为,内蒙古绒山羊属典型的北方山羊品种。 | 刘小林 常洪 任战军 耿社民 李相运 Ken Nozawa | 1998 | 西北农业学报1998，7，2： | 4 |
| 7 | Breakthrough therapy for peritoneal carcinomatosis of gastric cancer:Intraperitoneal chemotherapy with taxanes显示文摘The effect of chemotherapy on peritoneal carcinomatosis(PC) of gastric cancer remains unclear.Recently,the intraperitoneal(IP) administration of taxanes [e.g.,paclitaxel(PTX) and docetaxel(DOC)] during the perioperative period has shown promising results.Herein,we summarized the rationale and methodology for using IP chemotherapy with taxanes and reviewed the clinical results.IP administered taxanes remain in the IP space at an extremely high concentration for 48-72 h.The drug directly infiltrates peritoneal metastatic nodules from the surface and then produces antitumor effects,making it ideal for IP chemotherapy.There are two types of perioperative IP chemotherapy with taxanes: neoadjuvant intraperitoneal and systemic chemotherapy and sequential perioperative intraperitoneal chemotherapy(SPIC).In SPIC,patients receive neoadjuvant IP chemotherapy and the same regimen of IP chemotherapy after cytoreductive surgery(CRS) until disease progression.Usually,a taxane dissolved in 500-1000 m L of saline at ordinary temperature is administered through an IP access port on an outpatient basis.According to phase Ⅰ?studies,the recommended doses(RD) are as follows: IP DOC,45-60 mg/m2; IP PTX [without intravenous(IV) PTX],80 mg/m2; and IP PTX(with IV PTX),20 mg/m2.Phase Ⅱ studies have reported a median survival time of 14.4-24.6 mo with a 1-year overall survival of 67%-78%.A phase Ⅲ study comparing S-1 in combination with IP and IV PTX to S-1 with IV cisplatin started in 2011.The prognosis of patients who underwent CRS was better than that of those who did not; however,this was partly due to selection bias.Although several phase Ⅱ studies have shown promising results,a randomized controlled study is needed to validate the effectiveness of IP chemotherapy with taxanes for PC of gastric cancer. | Hironori Yamaguchi Joji Kitayama Hironori Ishigami Shinsuke Kazama Hiroaki Nozawa Kazushige Kawai Keisuke Hata Tomomichi Kiyomatsu Toshiaki Tanaka Junichiro Tanaka Takeshi Nishikawa Kensuke Otani Koji Yasuda Soichiro Ishihara Eiji Sunami Toshiaki Watanabe | 2015 | World Journal of Gastrointestinal Oncology2015，7，11： | 3 |
| 8 | 太行山羊遗传检测显示文摘应用随机整群抽样方法 ,对太行山羊的两个群体共 72只成年羊 ,用淀粉凝胶电泳法测定了 3 3个血液蛋白座位 ,并对毛色和外形特征进行了检测。结果表明 ,运铁蛋白 (Tf)、前白蛋白 -3 (Pa-3 )、肽酶 -B(Pep-B)、碱性磷酸酶 (Alp)、亮氨酸胺肽酶 (LAP)和酯酶 -D(Es-D) 6个血液蛋白座位表现多态性 ,多态位点比例为0 .1 81 8;1 2个类别 2 5种外型特征中 7个有变异体 ;4个毛色座位有变异。平均杂合度分析表明 ,太行山羊变异程度较大 (H =0 .0 5 5 5 ) ,说明太行山羊群体有效规模较大 ,目前尚未面临急待保种的局面。 | 刘小林 常洪 任战军 耿社民 NOZAWA Ken | 2002 | 西北农业学报2002，11，1： | 3 |
| 9 | Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w显示文摘Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese patients.Methods: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than 1.3.Conclusion: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second?line treatment option of mCRC. | Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim | 2016 | Chinese Journal of Cancer2016，35，12： | 3 |
| 10 | Impacts of Global Warming on Hydrological Cycles in the Asian Monsoon Region显示文摘The hydrologic changes and the impact of these changes constitute a fundamental global-warming- related concern. Faced with threats to human life and natural ecosystems, such as droughts, floods, and soil erosion, water resource planners must increasingly make future risk assessments. Though hydrological predictions associated with the global climate change are already being performed, mainly through the use of GCMs, coarse spatial resolutions and uncertain physical processes limit the representation of terrestrial water/energy interactions and the variability in such systems as the Asian monsoon. Despite numerous studies, the regional responses of hydrologic changes resulting from climate change remains inconclusive. In this paper, an attempt at dynamical downscaling of future hydrologic projection under global climate change in Asia is addressed. The authors conducted present and future Asian regional climate simulations which were nested in the results of Atmospheric General Circulation Model (AGCM) experiments. The regional climate model could capture the general simulated features of the AGCM. Also, some regional phenomena such as orographic precipitation, which did not appear in the outcome of the AGCM simulation, were successfully produced. Under global warming, the increase of water vapor associated with the warmed air temperature was projected. It was projected to bring more abundant water vapor to the southern portions of India and the Bay of Bengal, and to enhance precipitation especially over the mountainous regions, the western part of India and the southern edge of the Tibetan Plateau. As a result of the changes in the synoptic flow patterns and precipitation under global warming, the increases of annual mean precipitation and surface runoff were projected in many regions of Asia. However, both the positive and negative changes of seasonal surface runoff were projected in some regions which will increase the flood risk and cause a mismatch between water demand and water availability in the agricultural season. | Koji DAIRAKU Seita EMORI Toru NOZAWA | 2008 | Advances in Atmospheric Sciences2008，25，6： | 3 |
| 11 | 普萘洛尔治疗婴幼儿血管瘤:对血浆血管内皮细胞生长因子的作用显示文摘普萘洛尔治疗婴幼儿血管瘤(IH)效果显著,但其发病机制及其对血管内皮细胞生长因子(VEGF)的作用尚不清楚。该文旨在明确普萘洛尔的疗效和评估IH患者治疗后血浆VEGF的变化。35例IH患儿被纳入研究。口服普萘洛尔2.0 mg/kg·d,3次/d。以病变大小和颜色的视觉模拟量表(VAS)变化评估疗效。血浆VEGF浓度采用酶联免疫吸附试验测定,各组间进行比较。 | Ozeki M Nozawa A Hori T | 2017 | 中国口腔颌面外科杂志2017，15，1： | 3 |
| 12 | D-二聚体水平预测房颤患者中血栓栓塞事件显示文摘Background: Elevated coagulative molecular markers could reflect the prothromb otic state in the cardiovascular system of patients with non-valvular atrial fi brillation(NVAF). A prospective, cooperative study was conducted to determine wh ether levels of coagulative markers alone or in combination with clinical risk f actors could predict subsequent thromboembolic events in patients with NVAF. Met hods: Coagulative markers of prothrombin fragment 1 +2, D-dimer, platelet fact or 4, and β-thromboglobulin were determined at the enrollment in the prospecti ve study. Results: Of 509 patients with NVAF(mean age, 66.6±10.3 years), 263 pa tients were treated with warfarin(mean international normalized ratio, 1.86), an d 163 patients, with antiplatelet drugs. During an average follow-up period of 2.0 years, 31 thromboembolic events occurred. Event-free survival was significa ntly better in patients with D-dimer level< 150 ng/ml than in those with D-dim er level ≥150 ng/ml. Other coagulative markers, however, did not predict thromb oembolic events. Age(≥75 years), cardiomyopathies, and prior stroke or transien t ischemic attack were independent, clinical risk factors for thromboembolism. T hromboembolic risk in patients without the clinical risk factors was quite low(0 .7%/year) when D-dimer was< 150 ng/ml, but not low(3.8%/year) when D-dimer w as ≥150 ng/ml. It was > 5%/year in patients with the risk factors regardless o f D-dimer levels. This was also true when analyses were confined to patients tr eated with warfarin. Conclusions: D-dimer level in combination with clinical ri sk factors could effectively predict subsequent thromboembolic events in patient s with NVAF even when treated with warfarin. | Nozawa T. Inoue H. Hirai T. 黄浙勇(译) 杜媛(校) | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，9： | 2 |
| 13 | Hepatitis B virus infection in Indonesia显示文摘Approximately 240 million people are chronically infected with hepatitis B virus(HBV),75% of whom reside in Asia. Approximately 600000 of infected patients die each year due to HBV-related diseases or hepatocellular carcinoma(HCC). The endemicity of hepatitis surface antigen in Indonesia is intermediate to high with a geographical difference. The risk of HBV infection is high in hemodialysis(HD) patients,men having sex with men,and health care workers. Occult HBV infection has been detected in various groups such as blood donors,HD patients,and HIVinfected individuals and children. The most common HBV subgenotype in Indonesia is B3 followed by C1. Various novel subgenotypes of HBV have been identified throughout Indonesia,with the novel HBV subgenotypes C6-C16 and D6 being successfully isolated. Although a number of HBV subgenotypes have been discovered in Indonesia,genotyperelated pathogenicity has not yet been elucidated in detail. Therefore,genotype-related differences in the prognosis of liver disease and their effects on treatments need to be determined. A previous study conducted in Indonesia revealed that hepatic steatosis was associated with disease progression. Pre-S2 mutations and mutations at C1638 T and T1753 V in HBV/B3 have been associated with advanced liver diseases including HCC. However,drug resistance to lamivudine,which is prominent in Indonesia,remains obscure. Although the number of studies on HBV in Indonesia has been increasing,adequate databases on HBV infection are limited. We herein provided an overview of the epidemiology and clinical characteristics of HBV infection in Indonesia. | Shoji Kubo Shigekazu Takemura Shogo Tanaka Hiroji Shinkawa Takayoshi Nishioka Akinori Nozawa Masahiko Kinoshita Genya Hamano Tokuji Ito Yorihisa Urata | 2015 | World Journal of Gastroenterology2015，21，38： | 2 |
| 14 | Contrast-enhanced sonography of pancreatic carcinoma: correlations with pathological findings显示文摘 | Kazushi Numata Yutaka Ozawa Noritoshi Kobayashi Toru Kubota Hiroshi Shimada Akinori Nozawa Yukio Nakatani Kazuya Sugimori Kenichi Matsuo Toshio Imada Katsuaki Tanaka | 2005 | Journal of Gastroenterology2005，，6： | 2 |
| 15 | Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use:A case report显示文摘BACKGROUND Bevacizumab is an antiangiogenic agent,and that synergizes with chemotherapeutic drugs.When used in combination therapies,Bevacizumab is associated with adverse events such as hemorrhage,gastrointestinal perforation,delayed wound healing,and pneumothorax.However,the molecular mechanisms underlying these adverse events are not fully understood.CASE SUMMARY A 45-year-old female with multiple lung metastases that were derived from primary breast cancer,was placed on Bevacizumab+paclitaxel therapy,since this combination has a potent antitumor effect.She reported dyspnea before cycle 3,day 1 and we therefore ran a chest X-ray,which detected a right pneumothorax.The coronal plane computed tomography revealed that one solid mass rapidly necrosed and was replaced by a cavity that passed through the bronchus in the right lower lobe.The cavity eventually ruptured the pleura and made the bronchopleural fistula that led to this pneumothorax.Thoracic cavity drainage using an intercostal catheter was performed.On the 7th day of drainage,the patient was discharged from our hospital on recovery.Recurrence of pneumothorax was not reported,and continuation of chemotherapy was made possible by changing the regimen.CONCLUSION Patients with lung metastases surrounding the bronchi and on the pleura should be monitored for pneumothorax by Bevacizumab-containing chemotherapies. | Yuri Ozaki Akiyo Yoshimura Masataka Sawaki Masaya Hattori Naomi Gondo Haruru Kotani Yayoi Adachi Ayumi Kataoka Kayoko Sugino Nanae Horisawa Yuka Endo Kazuki Nozawa Shoko Sakamoto Hiroji Iwata | 2020 | World Journal of Clinical Oncology2020，11，7： | 2 |
| 16 | Large eddy simulation of the flow around a low-rise building immersed in a rough-wall turbulent boundary layer显示文摘 | Nozawa K Tamura T | 2002 | Journal of Wind Engineering and Industrial Aerodynamics2002，90，： | 2 |
| 17 | Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms显示文摘 | Ryonho Koh Kingo Hirasawa Sei Yahara Hiroyuki Oka Kazuya Sugimori Manabu Morimoto Kazushi Numata Atsushi Kokawa Takeshi Sasaki Akinori Nozawa Masataka Taguri Satoshi Morita Shin Maeda Katsuaki Tanaka | 2013 | Gastrointestinal Endoscopy2013，，： | 2 |
| 18 | Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment显示文摘 | Satoshi Kondo Tadahiro Takada Masaru Miyazaki Shuichi Miyakawa Kazuhiro Tsukada Masato Nagino Junji Furuse Hiroya Saito Toshio Tsuyuguchi Masakazu Yamamoto Masato Kayahara Fumio Kimura Hideyuki Yoshitomi Satoshi Nozawa Masahiro Yoshida Keita Wada Satoshi | 2008 | Journal of Hepato - Biliary - Pancreatic Surgery2008，，1： | 2 |
| 19 | Morphological traits and biochemical polymorphisms of Myanmar sheep显示文摘 | Tsunoda K Amano K Nozawa K | 2004 | Rep Soc Res Native Livestock2004，21，： | 1 |
| 20 | Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis 显示文摘 | Nozawa H Chiu C Hanahan D | 2006 | Proc Natl Acad Sci USA2006，103，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员